Dyne Therapeutics (DYN) to Release Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Dyne Therapeutics to post earnings of ($0.74) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Dyne Therapeutics Trading Up 0.7%

Shares of NASDAQ DYN opened at $15.38 on Thursday. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $25.00. The business has a fifty day moving average price of $18.09 and a 200 day moving average price of $16.76. The stock has a market capitalization of $2.20 billion, a P/E ratio of -4.20 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. HC Wainwright raised their target price on shares of Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Tudor Pickering set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday, December 9th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 target price on shares of Dyne Therapeutics in a research report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.41.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $84,000. Steward Partners Investment Advisory LLC lifted its position in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at about $111,000. Finally, Creative Planning lifted its holdings in shares of Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.